Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis

Biomaterials

Volumn 33, Issue 29, 2012, Pages 7174-7181

  Chu, Te Wei ^a   Yang, Jiyuan ^a   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

B cell; CD20; HPMA; Multivalency; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

B CELLS; CD20; HPMA; MULTIVALENCY; NON-HODGKIN'S LYMPHOMA; RITUXIMAB;

BIOMIMETICS; COPOLYMERS; MOLECULAR WEIGHT; MONOCLONAL ANTIBODIES; ONCOLOGY; PEPTIDES;

CELL DEATH;

ANTIBODY CONJUGATE; BIOMIMETIC MATERIAL; CASPASE 3; CELL RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; SULFIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BIODEGRADABILITY; CELL VIABILITY; CHEMICAL BINDING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; POLYMERIZATION; PRIORITY JOURNAL; RAJI CELL; REVERSIBLE ADDITION FRAGMENTATION CHAIN TRANSFER POLYMERIZATION; TIME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; APOPTOSIS; BIOMIMETICS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN FAB FRAGMENTS; LYMPHOMA, NON-HODGKIN; METHACRYLATES; MICROSCOPY, CONFOCAL; MODELS, CHEMICAL; POLYMERS; TIME FACTORS;

EID: 84864321505     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.024     Document Type: Article

References (41)

1. Couvreur P., Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006, 23(7):1417-1450.
2. Kopeček J. Smart and genetically engineered biomaterials and drug delivery systems. Eur J Pharm Sci 2003, 20(1):1-16.
3. Kopeček J., Kopečková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 2010, 62(2):122-149.
4. Ulbrich K., Šubr V. Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliv Rev 2010, 62(2):150-166.
5. Vicent M.J., Ringsdorf H., Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev 2009, 61(13):1117-1120.
6. Wu K., Liu J., Johnson R.N., Yang J., Kopeček J. Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. Angew Chem Int Ed Engl 2010, 49(8):1451-1455.
7. Wu K., Yang J., Liu J., Kopeček J. Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy. J Control Release 2012, 157(1):126-131.
8. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62(1):10-29.
9. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980, 125(4):1678-1685.
10. Cheson B.D., Leonard J.P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008, 359(6):613-626.
11. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008, 59:237-250.
12. Allison M. PML problems loom for rituxan. Nat Biotechnol;28(2):105-6.
13. Major E.O. Reemergence of PML in natalizumab-treated patients-new cases, same concerns. N Engl J Med 2009, 361(11):1041-1043.
14. Lands L.C. New therapies, new concerns: rituximab-associated lung injury. Pediatr Nephrol 2010, 25(6):1001-1003.
15. Kamei K., Ito S., Iijima K. Severe respiratory adverse events associated with rituximab infusion. Pediatr Nephrol 2010, 25(6):1193.
16. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 2002, 99(3):754-758.
17. van der Kolk L.E., Grillo-López A.J., Baars J.W., Hack C.E., van Oers M.H. Complement activation plays a key role in the side effects of rituximab treatment. Br J Haematol 2001, 115(4):807-811.
18. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22(47):7359-7368.
19. de Haij S., Jansen J.H.M., Boross P., Beurskens F.J., Bakema J.E., Bos D.L., et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010, 70(8):3209-3217.
20. Golay J., Cittera E., Di Gaetano N., Manganini M., Mosca M., Nebuloni M., et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006, 91(2):176-183.
21. Stein R., Qu Z., Chen S., Solis D., Hansen H.J., Goldenberg D.M. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood 2006, 108(8):2736-2744.
22. Zhang N., Khawli L.A., Hu P., Epstein A.L. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 2005, 11(16):5971-5980.
23. Popov J., Kapanen A.I., Turner C., Ng R., Tucker C., Chiu G., et al. Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity. Nanomedicine (Lond) 2011, 6(9):1575-1591.
24. Ghetie M.A., Bright H., Vitetta E.S. Homodimers but not monomers of rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001, 97(5):1392-1398.
25. Rossi E.A., Goldenberg D.M., Cardillo T.M., Stein R., Wang Y., Chang C.-H. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res 2008, 68(20):8384-8392.
26. Johnson R.N., Kopečková P., Kopeček J. Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20. Bioconjug Chem 2009, 20(1):129-137.
27. Johnson R.N., Kopečková P., Kopeček J. Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates. Biomacromolecules 2012, 13(3):727-735.
28. Kopeček J., Bažilová H. Poly[N-(2-hydroxypropyl)methacrylamide]. I. Radical polymerization and copolymerization. Eur Polym J 1973, 9(1):7-14.
29. Pan H., Yang J., Kopečková P., Kopeček J. Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction. Biomacromolecules 2011, 12(1):247-252.
30. Starcher B. A ninhydrin-based assay to quantitate the total protein content of tissue samples. Anal Biochem 2001, 292(1):125-129.
31. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82(1):70-77.
32. Omelyanenko V., Kopečková P., Gentry C., Shiah J.G., Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. Influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J Drug Target 1996, 3(5):357-373.
33. Luo K., Yang J., Kopečková P., Kopeček J. Biodegradable multiblock poly[N-(2-hydroxypropyl)methacrylamide] via reversible addition-fragmentation chain transfer polymerization and click chemistry. Macromolecules 2011, 44(8):2481-2488.
34. Yang J., Luo K., Pan H., Kopečková P., Kopeček J. Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelic polyHPMA conjugates. React Funct Polym 2011, 71(3):294-302.
35. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995, 1237(2):99-108.
36. Lammers T., Kühnlein R., Kissel M., Šubr V., Etrych T., Pola R., et al. Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J Control Release 2005, 110(1):103-118.
37. Shiah J.-G., Dvořák M., Kopečková P., Sun Y., Peterson C.M., Kopeček J. Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice. Eur J Cancer 2001, 37(1):131-139.
38. Allmeroth M., Moderegger D., Biesalski B., Koynov K., Rösch F., Thews O., et al. Modifying the body distribution of HPMA-based copolymers by molecular weight and aggregate formation. Biomacromolecules 2011, 12(7):2841-2849.
39. Kopeček J., Kopečková P. Design of polymer-drug conjugates. Drug delivery in oncology 2012, vol. 2:485-512. Wiley-VCH, Weinheim. F. Kratz, P. Senter, H. Steinhagen (Eds.).
40. Ding H., Kopečková P., Kopeček J. Self-association properties of HPMA copolymers containing an amphipathic heptapeptide. J Drug Target 2007, 15(7-8):465-474.
41. Hervé L. Nuclear apoptosis detection by flow cytometry: influence of endogenous endonucleases. Exp Cell Res 2002, 277(1):1-14.